Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 29, 2014CareFusion, Terumo Sign Distribution Agreement For IV Catheters
SAN DIEGO, CA, Jan. 29, 2014 /PRNewswire/ – CareFusion (NYSE:CFN), a leading global medical technology company, and Terumo Corporation, the largest medical technology company in Japan, today...
-
Jan 28, 2014
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 54.5 cents per common share payable on March 31, 2014 to holders of record on March...
-
Jan 14, 2014
BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 28,...
-
Jan 13, 2014BD MAX(TM) MRSA XT Assay with eXTended Detection Technology Receives FDA Clearance
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has received FDA clearance to market the BD MAX(TM) MRSA XT
-
Jan 10, 2014
SAN DIEGO, CA, Jan. 9, 2014 /PRNewswire/ – CareFusion Corporation (NYSE: CFN) today announced plans to release second quarter fiscal 2014 results on Monday, Feb. 3, following the close of...
-
Jan 9, 2014
SAN DIEGO, CA, Jan. 9, 2014 /PRNewswire/ – CareFusion Corp. (NYSE: CFN) today issued the following statement regarding a previously disclosed settlement agreement: Today, the U.S. Department of...
-
Jan 7, 2014
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2014 earnings conference call on Tuesday, February 4, 2014, at 8:00...
-
Jan 7, 2014Advances BD Diagnostics' Point-of-Care Strategy
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired Alverix, Inc., a privately-held diagnostic instrument company...
-
Jan 5, 2014In response to a recent media story regarding the validity of a CareFusion-funded clinical study, CareFusion issued the following statement:
Our products are safe and effective. In particular, our skin prep product, ChloraPrep, has been proven effective when used in conjunction with best clinical practices to effectively kill...